- Home
- MDIA vs ATNM Comparison
MDIA vs ATNM Comparison
Compare MDIA & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDIA | ATNM |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 45.2M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MDIA | ATNM |
|---|---|---|
| Price | $0.61 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 30.3K | ★ 118.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.00 | 30.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,571,000.00 | $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.05 | N/A |
| 52 Week Low | $0.54 | $1.02 |
| 52 Week High | $1.60 | $1.95 |
Technical Indicators
Market Signals| Indicator | MDIA | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 50.89 |
| Support Level | $0.56 | $1.02 |
| Resistance Level | $0.65 | $1.71 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 78.96 | 78.12 |
Price Performance
Historical ComparisonAbout MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.